TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors

SEATTLE, March 19, 2015 – TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company’s Board of Directors. David brings 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical and healthcare products. He has a successful track record of building, developing, operating and…

TapImmune Appoints John Bonfiglio as Strategic Advisor

Accomplished Biotech CEO to provide Capital Market, Financing and Drug Development Expertise SEATTLE, Feb. 25, 2015 – TapImmune Inc. (TPIV) has pleasure in announcing the appointment of John Bonfiglio, Ph.D., MBA as a Strategic Advisor. John is a highly successful Biotech CEO with broad experience in corporate strategy and financing, market interactions and business development.…

TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer

SEATTLE, Feb. 23, 2015 – TapImmune, (TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including metastatic disease, is pleased to announce Patrick D. Yeramian, MD, MBA, has been appointed Consulting Medical Director. He will lead TapImmune’s clinical development programs for folate receptor alpha and Her2/neu multi-epitope cancer technologies.…

TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015

TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015 Seattle, WA – February 20, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today Dr. Glynn Wilson, Chairman & CEO of TapImmune,…

TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations

TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations Seattle, WA & NY, NY – February 19, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today the Company’s management team has selected New York City based…

Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials

Analysis of Phase I Trial indicates Safety and Positive Immune Response Data in 21 of 21 Patients Administered Folate Receptor Alpha Vaccine for Breast and Ovarian Cancers January 12, 2015, Seattle WA, TapImmune Inc. (OTCQB: TPIV) is extremely pleased to report the completion of data analysis from all 21 evaluable patients treated in a Phase…

TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering

Exercise in Full of Strategically Designed Warrant Package Would Result in $34,404,000 in Additional Funding Seattle, January 12, 2015 — TapImmune, Inc. (the “Company”), (otcqb:TPIV), today announced that it has entered into a definitive agreement with institutional investors for a registered direct placement of 7,320,000 units at $0.20 per unit, with each “unit” consisting of…